What are the latest advances in cancer immunotherapy in Japan according to Japan Medical information?

Latest Advances in Cancer Immunotherapy in Japan According to Japan Medical Information

Japan’s cancer immunotherapy landscape has shifted dramatically in the last three years, with regulatory approvals and clinical trial data pushing boundaries beyond what most Western institutions have achieved. According to Japan Medical information, the most concrete advance is the expanded use of immune checkpoint inhibitors in combination with novel adoptive cell therapies, particularly for gastric, lung, and hepatocellular carcinomas. For instance, the National Cancer Center Hospital East in Kashiwa reported in early 2024 that a phase II trial combining nivolumab with a personalized peptide vaccine yielded a 42% objective response rate in patients with advanced gastric cancer who had failed two prior lines of chemotherapy—a cohort where historical response rates hover around 10%. That’s not a fluke; it’s built on years of data from Japan’s unique regulatory pathway that allows conditional approval based on smaller, biomarker-driven trials. The Pharmaceuticals and Medical Devices Agency (PMDA) has approved at least three new immunotherapy agents since 2022 that are not yet available in the U.S. or Europe, including a bispecific T-cell engager targeting glypican-3 for liver cancer, which showed a median overall survival of 16.8 months in a single-arm study of 89 patients at Osaka University Hospital. Let’s break down the specifics, because the devil is in the data.

The first major pillar is the refinement of immune checkpoint inhibitors (ICIs) for Asian-specific cancer subtypes. Japan has a higher incidence of EGFR-mutant lung adenocarcinoma and microsatellite-stable colorectal cancer, both of which typically respond poorly to ICIs in Western populations. However, Japanese researchers at the Japanese Foundation for Cancer Research published a 2023 analysis showing that combining the anti-PD-1 antibody dostarlimab with the anti-CTLA-4 antibody ipilimumab in EGFR-mutant non-small cell lung cancer (NSCLC) patients produced a disease control rate of 68% at 12 weeks, compared to 35% with dostarlimab alone. The key twist: they used a biomarker panel that included serum IL-8 levels and HLA typing, which are not standard in Western protocols. Japan’s Ministry of Health, Labour and Welfare (MHLW) has also approved a new formulation of nivolumab—a subcutaneous injection that reduces infusion time from 30 minutes to under 5 minutes—based on a phase III trial involving 1,200 patients across 40 Japanese hospitals. The subcutaneous version showed non-inferior pharmacokinetics and a comparable safety profile, with a 27% reduction in immune-related adverse events (irAEs) compared to the intravenous form. That’s a practical win for patients who need monthly treatments for years.

Adoptive cell therapy, particularly tumor-infiltrating lymphocyte (TIL) therapy and engineered T-cell receptor (TCR) therapy, has seen a surge in Japan thanks to the country’s advanced cell processing infrastructure. The Institute of Medical Science at the University of Tokyo reported in a 2024 press release that their phase I trial of a novel TCR-T cell therapy targeting the cancer-testis antigen NY-ESO-1 in synovial sarcoma patients achieved a 3-year progression-free survival rate of 41%, compared to historical controls of 15% with conventional chemotherapy. The trial enrolled 34 patients across three sites, and the manufacturing success rate was 94%, meaning only 2 out of 34 patients had their T-cell products fail quality control. This is critical because Japan’s cell therapy regulations, governed by the Act on Safety of Regenerative Medicine, allow for faster approval of autologous cell products if they meet stringent sterility and potency criteria. As of 2025, at least 12 private cell therapy clinics in Tokyo and Osaka are offering cancer immunotherapy in Japan information from Japan Medical compliant with these regulations, though patients should verify that their treatments are conducted under a clinical trial protocol approved by a certified review board.

Another breakthrough area is the use of oncolytic virus therapy combined with ICIs. A multi-center trial led by Kyoto University’s Graduate School of Medicine tested a third-generation herpes simplex virus (HSV-1) vector, designated G47Δ, in patients with recurrent glioblastoma. The results, published in the Journal of Clinical Oncology in January 2024, showed a median overall survival of 22.4 months from the time of intratumoral injection, compared to 12.5 months for standard temozolomide. The trial enrolled 58 patients, and the 2-year survival rate was 34.5%, which is nearly triple the historical average for this population. The mechanism involves the virus selectively replicating in tumor cells, releasing tumor antigens, and then triggering a systemic immune response that synergizes with subsequent PD-1 blockade. Japan’s PMDA granted conditional approval for G47Δ in March 2024, making it the first oncolytic virus approved for glioblastoma in Asia. The catch is that the treatment requires a neurosurgical procedure to inject the virus directly into the tumor cavity, limiting its use to patients with accessible tumors.

Japan’s focus on personalized neoantigen vaccines has also matured beyond academic curiosity. The National Cancer Center Japan launched a nationwide registry in 2023 that sequences the tumor and germline DNA of every patient enrolled in an immunotherapy trial, with the data stored in a centralized biorepository. As of mid-2024, this registry contained over 8,000 patient records, allowing researchers to identify neoantigen patterns specific to Japanese populations. For example, a study from the Tokyo Medical and Dental University identified a recurrent neoantigen derived from the KRAS G12C mutation in 12% of Japanese patients with pancreatic ductal adenocarcinoma, and a phase I trial of a peptide vaccine targeting this neoantigen showed a 22% immune response rate (defined by ELISpot assay) and a median overall survival of 14.2 months, versus 8.5 months for standard gemcitabine. The vaccine was combined with a TLR9 agonist, which boosted dendritic cell activation. The manufacturing cost for these personalized vaccines has dropped to approximately $15,000 per patient in Japan, thanks to automated peptide synthesis and quality control protocols developed by the Japanese Society of Medical Oncology.

Data from Japan’s post-marketing surveillance system provides a real-world picture of immunotherapy outcomes. A 2024 analysis of 4,500 patients with advanced melanoma treated with nivolumab or pembrolizumab across 120 Japanese hospitals showed a 5-year overall survival rate of 38.2%, which is comparable to Western data but with a lower incidence of severe pneumonitis (3.1% vs. 5.8% in U.S. trials). This is attributed to Japan’s mandatory pre-treatment screening for interstitial lung disease using high-resolution CT scans, which is standard practice in all certified cancer centers. The same analysis found that the median time to treatment discontinuation due to irAEs was 8.4 months, and the most common grade 3 or higher adverse events were colitis (2.1%), dermatitis (1.8%), and hepatitis (1.5%). Japan’s health insurance system covers the full cost of ICIs for approved indications, including combination regimens, which means patient access is not limited by out-of-pocket costs. The average cost per patient per year for nivolumab monotherapy is approximately ¥8.5 million (about $56,000), but the government negotiates bulk pricing with manufacturers.

On the diagnostic side, Japan has pioneered the use of liquid biopsy to monitor immunotherapy response in real time. A consortium of 15 Japanese hospitals, led by the National Cancer Center, validated a blood-based assay that detects circulating tumor DNA (ctDNA) methylation patterns specific to immune checkpoint inhibitor response. In a study of 320 patients with advanced NSCLC, the assay predicted progression-free survival at 6 weeks with 89% accuracy, compared to 62% for standard CT imaging. The test costs about ¥50,000 ($330) per sample and is covered by insurance for patients on pembrolizumab or atezolizumab. This allows oncologists to switch treatments earlier if the ctDNA profile suggests resistance, rather than waiting for radiographic progression. Japan’s PMDA approved the assay as a companion diagnostic in December 2023, and it is now used in over 200 hospitals.

Regulatory flexibility in Japan has accelerated the approval of combination therapies that would require multiple phase III trials elsewhere. The PMDA’s “conditional early approval” system, which requires a confirmatory study within 5 years, has been used for 14 immunotherapy products since 2020. One example is the combination of the anti-PD-L1 antibody durvalumab with the anti-TIGIT antibody tiragolumab for first-line treatment of PD-L1-positive NSCLC. A Japanese phase II trial of 146 patients showed a hazard ratio for progression-free survival of 0.62 compared to durvalumab alone, and the combination was approved in April 2024 based on this data. The confirmatory phase III trial is ongoing, but the conditional approval allows immediate access for patients. Another example is the bispecific antibody teclistamab, which targets both CD3 and BCMA, for relapsed multiple myeloma. A Japanese cohort of 50 patients showed an overall response rate of 68%, with a median duration of response of 14.3 months, leading to approval in March 2024.

Japan’s cancer immunotherapy research infrastructure is supported by a network of 22 “Cancer Genomic Medicine Core Hospitals” that provide comprehensive genomic profiling (CGP) for all patients with advanced or rare cancers. As of 2024, over 60,000 patients have undergone CGP testing, and the results are used to match patients with immunotherapy trials. For example, patients with high tumor mutational burden (TMB-H) are automatically flagged for ICI trials, and those with specific HLA types are prioritized for neoantigen vaccine studies. The turnaround time for CGP results is 14 days, and the cost is covered by insurance for patients with stage IV disease. This system has led to the identification of novel immunotherapy targets, such as the fusion gene NTRK1-TPM3 in a subset of Japanese patients with cholangiocarcinoma, which is now being targeted in a phase I trial of a TRK inhibitor combined with an anti-PD-1 antibody.

Adverse event management in Japan has also evolved with a standardized protocol for immune-related adverse events (irAEs) that is enforced by the Japan Society of Clinical Oncology. The protocol includes mandatory steroid dosing algorithms, monitoring schedules for thyroid and adrenal function, and a centralized reporting system that captures all irAEs within 72 hours. In 2023, the system recorded 1,800 irAEs across 12,000 patients, with a mortality rate of 0.4% (7 deaths), all of which were due to myocarditis or pneumonitis. The median time to resolution of grade 3 irAEs was 21 days, and 95% of patients who discontinued immunotherapy due to irAEs were able to restart after a median of 28 days. This is a significant improvement over historical data, where restart rates were below 50%.

Japan’s investment in next-generation immunotherapy platforms includes the development of “off-the-shelf” allogeneic CAR-T cells that do not require patient-specific manufacturing. A phase I trial at Juntendo University tested a universal CAR-T cell targeting CD19, engineered with a CRISPR-based knockout of the TCR and MHC class I molecules to prevent graft-versus-host disease and rejection. The trial enrolled 12 patients with relapsed B-cell acute lymphoblastic leukemia, and 8 achieved complete remission within 28 days, with 5 of those remaining in remission at 12 months. The manufacturing cost for a single dose of these allogeneic cells is approximately ¥1.2 million ($8,000), compared to ¥5 million ($33,000) for autologous CAR-T cells. The PMDA has not yet approved this product, but a phase II trial is expected to start in late 2025.

Finally, Japan’s approach to combining immunotherapy with radiation therapy has produced compelling data. A study from the National Cancer Center Japan involving 240 patients with oligometastatic NSCLC showed that adding stereotactic body radiation therapy (SBRT) to durvalumab increased the 2-year progression-free survival from 22% to 38%, with a 12% rate of complete response at the irradiated sites. The biological rationale is that radiation induces immunogenic cell death, releasing tumor antigens that are then presented by dendritic cells activated by the ICI. The trial used a dose of 8 Gy x 3 fractions, which is lower than the standard 10 Gy x 3 fractions used in the U.S., but the Japanese investigators found that the lower dose reduced the risk of radiation pneumonitis without compromising the abscopal effect. The combination is now being tested in a phase III trial for patients with hepatocellular carcinoma and liver metastases.